550 related articles for article (PubMed ID: 20027122)
1. Common genetic variations of the renin-angiotensin-aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension.
Hannila-Handelberg T; Kontula KK; Paukku K; Lehtonen JY; Virtamo J; Tikkanen I; Hiltunen TP
J Hypertens; 2010 Apr; 28(4):771-9. PubMed ID: 20027122
[TBL] [Abstract][Full Text] [Related]
2. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition.
Hingorani AD; Jia H; Stevens PA; Hopper R; Dickerson JE; Brown MJ
J Hypertens; 1995 Dec; 13(12 Pt 2):1602-9. PubMed ID: 8903618
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of antihypertensive treatment.
Arnett DK; Claas SA; Glasser SP
Vascul Pharmacol; 2006 Feb; 44(2):107-18. PubMed ID: 16356784
[TBL] [Abstract][Full Text] [Related]
4. [Effect of inhibition of converting enzyme by captopril on arterial pressure, renin and aldosterone in essential hypertension].
Posadas C; Sánchez G; Boyer JL; Delmar M; Serrano PA
Arch Inst Cardiol Mex; 1982; 52(4):295-300. PubMed ID: 6291470
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives.
Bozkurt O; Verschuren WM; van Wieren-de Wijer BM; Knol MJ; de Boer A; Grobbee DE; Geerlings MI; Heerdink ER; Klungel OH
J Hum Hypertens; 2008 Nov; 22(11):774-80. PubMed ID: 18563171
[TBL] [Abstract][Full Text] [Related]
6. Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus.
Volkan-Salanci B; Dagdelen S; Alikasifoglu M; Erbas T; Hayran M; Erbas B
J Renin Angiotensin Aldosterone Syst; 2009 Mar; 10(1):41-50. PubMed ID: 19286758
[TBL] [Abstract][Full Text] [Related]
7. Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians.
Filigheddu F; Argiolas G; Bulla E; Troffa C; Bulla P; Fadda S; Zaninello R; Degortes S; Frau F; Pitzoi S; Glorioso N
Pharmacogenomics; 2008 Oct; 9(10):1419-27. PubMed ID: 18855530
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men.
Donner KM; Hiltunen TP; Suonsyrjä T; Hannila-Handelberg T; Tikkanen I; Antikainen M; Hirvonen A; Kontula K
J Hypertens; 2009 Oct; 27(10):2001-9. PubMed ID: 19593208
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors in hypertension: a review.
Salvetti A; Pedrinelli R; Arzilli F; Abdel-Haq B; Magagna A; Lucarini A; Graziadei L; Nuccorini A; Taddei S
Int J Clin Pharmacol Res; 1985; 5(6):429-38. PubMed ID: 3005182
[TBL] [Abstract][Full Text] [Related]
10. Influence of renin angiotensin system gene polymorphisms on visit-to-visit blood pressure variability in hypertensive patients.
Kawai T; Ohishi M; Onishi M; Takeya Y; Ito N; Kato N; Yamamoto K; Kamide K; Rakugi H
Am J Hypertens; 2012 Dec; 25(12):1249-55. PubMed ID: 22932704
[TBL] [Abstract][Full Text] [Related]
11. Angiotensinogen genotype predicts abnormal renal hemodynamics in young hypertensive patients.
Patel TV; Williams GH; Fisher ND
J Hypertens; 2008 Jul; 26(7):1353-9. PubMed ID: 18551010
[TBL] [Abstract][Full Text] [Related]
12. Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.
Steele JL; Henik RA; Stepien RL
Vet Ther; 2002; 3(2):157-66. PubMed ID: 19750747
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic possibilities for the inhibition of the renin-angiotensin-aldosterone system].
Abrahám G; Légrády P
Orv Hetil; 2003 May; 144(18 Suppl 1):892-5. PubMed ID: 12785232
[TBL] [Abstract][Full Text] [Related]
14. [Effect of CYP11B2 gene -344T/C polymorphism on renin-angiotensin-aldosterone system activity and blood pressure response to hydrochlorothiazide].
Li Y; Yang P; Wu SL; Yuan JX; Wu Y; Zhao DD; Xu S; Zhao LP; Sun MJ; Chu LM; Lu DS
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Feb; 29(1):68-71. PubMed ID: 22311496
[TBL] [Abstract][Full Text] [Related]
15. Tagging SNPs in REN, AGTR1 and AGTR2 genes and response of renin activity, angiotensin II and aldosterone concentrations to antihypertensive treatment in Kazakans.
Yan W; Zhang Y; Shan Z; Wang Q; Huang Y; Wang C; Yan K
J Renin Angiotensin Aldosterone Syst; 2011 Dec; 12(4):581-7. PubMed ID: 21810897
[TBL] [Abstract][Full Text] [Related]
16. [Clinical experience with an oral angiotensin I-converting enzyme inhibitor in hypertensive patients: effects on blood pressure and the renin-aldosterone system by a single dose (author's transl)].
Mizuno K; Shigetomi S; Haruyama K; Matsui J; Gotho M; Fukuchi S
Nihon Jinzo Gakkai Shi; 1980 Jan; 22(1):1-11. PubMed ID: 6247526
[No Abstract] [Full Text] [Related]
17. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
Krum H; Gilbert RE
J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
[TBL] [Abstract][Full Text] [Related]
18. Effects of enalapril maleate on blood pressure, renin-angiotensin-aldosterone system, and peripheral sympathetic activity in essential hypertension.
Cerasola G; Cottone S; D'Ignoto G; Grasso L; Carone MB; Carapelle E; Contorno A
Clin Ther; 1987; 9(4):390-9. PubMed ID: 3038326
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension.
Azizi M; Guyene TT; Chatellier G; Ménard J
J Hypertens; 1994 Apr; 12(4):419-27. PubMed ID: 8064166
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
